黄蜀葵花对比氯沙坦钾治疗IgA肾病:随机对照试验研究方案
本研究为多中心、前瞻性、双盲、双模拟、非劣效性随机对照试验,计划在中国100个中心纳入约1600例经肾活检确诊的IgA肾病患者,随机分配至黄葵胶囊组(2.5 g,每日三次)或氯沙坦钾组(100 mg/d),随访48周,主要结局为治疗48周后24小时蛋白尿较基线的变化。
要点
- 黄葵胶囊组用法为2.5 g每日三次,氯沙坦钾组为100 mg/d,随访48周。
- 主要结局为治疗48周后24小时蛋白尿较基线的变化。
- 次要结局包括eGFR变化及终点事件发生率。
核心结论
- 本研究规模与范围足以评估黄蜀葵花对比氯沙坦钾治疗IgA肾病的疗效与安全性,结果可能为IgA肾病提供新的有效且安全的治疗策略。
研究设计与样本
- 多中心、前瞻性、双盲、双模拟随机对照非劣效性临床试验,计划在中国100个中心纳入约1600例经肾活检确诊的IgA肾病患者,随访长达48周。
- 患者随机分配至黄蜀葵花组(黄葵胶囊2.5 g,每日三次)或氯沙坦钾组(氯沙坦钾100 mg/d)。
关键数值与推荐
- 主要结局为治疗48周后24小时蛋白尿较基线的变化。
- 次要结局包括治疗48周后估算肾小球滤过率(eGFR)较基线的变化及终点事件发生率(蛋白尿≥3.5 g/24 h、血清肌酐翻倍或接受血液净化治疗)。
- 24小时蛋白尿和eGFR在第0、4、12、24、36和48周测量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide, but effective therapy remains limited and many patients progress to end-stage renal disease (ESRD). Only angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin-receptor blockers (ARB) show a high level of evidence (1B level) of being of value in the treatment for IgAN according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. However, traditional Chinese medicine has raised attention in kidney disease research. Abelmoschus manihot, a single medicament of traditional Chinese medicine has shown therapeutic effects in primary glomerular disease according to the randomized controlled clinical trial that we have completed. Here, we conduct a new study to assess the efficacy and safety of Abelmoschus manihot in IgAN. Also, this study is currently the largest double-blind, randomized controlled registered clinical research for the treatment of IgAN. METHODS: We will conduct a multicenter, prospective, double-blind, double-dummy randomized controlled study. The study is designed as a noninferiority clinical trial. Approximately 1600 biopsy-proven IgAN patients will be enrolled at 100 centers in China and followed up for as long as 48 weeks. IgAN patients will be randomized assigned to the Abelmoschus manihot group (in the form of a huangkui capsule, 2.5 g, three times per day) and the losartan potassium group (losartan potassium, 100 mg/d). The primary outcome is the change in 24-h proteinuria from baseline after 48 weeks of treatment. Change in estimated glomerular filtration rate (eGFR) from baseline after 48 weeks of treatment, the incidence of endpoint events (proteinuria ≥3.5 g/24 h, the doubling of serum creatinine, or receiving blood purification treatment) are the secondary outcomes. Twenty-four-hour proteinuria and eGFR are measured at 0, 4, 12, 24, 36 and 48 weeks. DISCUSSION: This study will be of sufficient size and scope to evaluate the efficacy and safety of Abelmoschus manihot compared to losartan potassium in treating patients with IgAN. The results of this study may provide a new, effective and safe treatment strategy for IgAN. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02231125 . Registered on 30 August 2014.
引用
- Li P, Chen YZ, Lin HL, et al. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28395659. doi:10.1186/s13063-016-1774-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。